TrialClinical rheumatology2022

Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study.

Jinmei Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.